RxDoctor Payments Data

Marshal Mirviss, MD

Internal Medicine · Milwaukee, WINPI 1205820958

Payments from drug & device makers

$603in general payments, 2019–2025

Across 43 payments — averaging $14.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$121
  • AbbVie$90
  • Pfizer$76
  • Merck$68
  • Novartis$46
  • Novo Nordisk$35
  • plus $167 from 7 others

What the payments were for

  • Food & beverage$59198%
  • Education$122%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$603 in reported general payments places this provider in the 85th percentile of 1,411 internal medicine providers in Wisconsin.

See all internal medicine providers in Wisconsin

Medicare billing

Part B allowed, 2024
$108,090
Medicare patients
271
Services billed
1,245

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate178$200,763
TrulicityDulaglutide131$166,297
EliquisApixaban172$156,989
Trelegy ElliptaFluticasone/Umeclidin/Vilanter161$120,170
OzempicSemaglutide84$115,343
JardianceEmpagliflozin45$60,335
MyrbetriqMirabegron104$59,050
XareltoRivaroxaban47$41,702
RybelsusSemaglutide25$40,188
TradjentaLinagliptin27$38,170
LinzessLinaclotide61$36,020
JanumetSitagliptin Phos/Metformin Hcl32$34,655
Breo ElliptaFluticasone/Vilanterol50$23,857
Janumet XrSitagliptin Phos/Metformin Hcl15$23,693
VascepaIcosapent Ethyl29$19,855

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet, Janumet Xr, Dulera$68$264,560239 claims
Lilly USA, LLCTrulicity$15$166,297131 claims
PfizerEliquis$76$156,989172 claims
Novo NordiskOzempic, Rybelsus$35$155,530109 claims
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat, Spiriva Respimat, Stiolto Respimat$33$134,242131 claims
AbbVieLinzess, Synthroid$90$41,857134 claims
AstraZenecaSymbicort$121$4,11211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,411 internal medicine providers in Wisconsin.

Other internal medicine in Milwaukee

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →